Goldman Sachs Gains Confidence In Market Rebound, Upgrades GE Healthcare Amid China Recovery Hopes

Group 1 - U.S. President Donald Trump announced a 25% tariff on imported goods from Mexico and Canada, and a doubling of tariffs on Chinese goods to 20% [1] - China retaliated by imposing its own tariffs on certain U.S. goods, sanctioning American companies, and planning to file a complaint with the World Trade Organization [1] - China banned imports of genetic sequencers from Illumina Inc [1] Group 2 - Goldman Sachs is optimistic about market stabilization and recovery in 2025, driven by rising demand and increased stimulus [2] - Analysts at Goldman Sachs see capital equipment markets at a turning point following a visit to China, emphasizing innovation as a key advantage [2] Group 3 - Goldman Sachs has upgraded GE Healthcare Inc from Neutral to Buy, raising the price target from $85 to $100 [3] - The analyst maintains a balanced view on GE Healthcare, projecting stable 4-5% growth in the base business, while facing headwinds in the China market [4] - The forecast for GE Healthcare's China sales is expected to return to 2023 levels by 2026, a revision from previous expectations of a rebound by 2028 [4] Group 4 - GE Healthcare stock was reported at $85.74, reflecting a 0.45% increase [5]